Compounds > 3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide

3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide and Vomiting

3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide has been researched along with Vomiting* in 1 studies

Trials

1 trial(s) available for 3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide and Vomiting

ArticleYear
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-15, Volume: 23, Issue:16

    Topics: Adamantane; Adult; Aged; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Treatment Outcome; Vomiting; Young Adult

2017